SEARCH

SEARCH BY CITATION

Keywords:

  • anakinra;
  • CHOP;
  • multicentric Castleman disease;
  • tocilizumab

Abstract

Castleman disease is a rare lymphoproliferative disorder, which presents in a unicentric or multicentric fashion. Multicentric Castleman disease (MCD) is associated with significant systemic symptoms, in part related to the underlying role of interleukin-6 in disease pathogenesis. Treatment for MCD has not been well established and prognosis has historically been poor. We present a case of severe MCD in a pediatric patient who has shown sustained remission following multi-agent chemotherapy and targeted maintenance therapy with the interleukin-6 receptor inhibitor, tocilizumab. This represents the first case report of sustained remission of MCD in a pediatric patient following discontinuation of tocilizumab therapy. Pediatr Blood Cancer 2014;61:737–739. © 2013 Wiley Periodicals, Inc.